Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial (Preprint)
22 Mar, 2020Background
Chloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and
reported to be efficient in Chinese COV-19 patients. We evaluate the role of
hydroxychloroquine on respiratory viral loads.
Patients and methods
Patients were included in a single arm protocol to receive 600mg of hydroxychloroquine daily
and their viral load in nasal swabs was tested daily. Depending on their clinical presentation,
azithromycin was added to the treatment. Untreated patients from another center and cases
refusing the protocol were included as negative controls. Presence and absence of virus at
Day6-post inclusion was considered the end point.
Results
Twenty cases were treated in this study and showed a significant reduction of the viral
carriage at D6-post inclusion compared to controls, and much lower average carrying duration
than reported of untreated patients in the literature. Azithromycin added to
hydroxychloroquine was significantly more efficient for virus elimination.
Conclusion
Hydroxychloroquine is significantly associated with viral load reduction/disappearance in
COVID-19 patients and its effect is reinforced by azithromycin.